Publications: Stephen Ezell

China has utilized numerous illegitimate tools in pursuit of global leadership in biopharmaceutical manufacturing, including IP theft, forced labor, and stealing genetic information. This must be met with a swift and forceful response from U.S. policymakers.

China is becoming an increasingly capable competitor in the global pharmaceutical industry, with growing strengths at every level of the biopharmaceutical supply chain. Responding to this challenge will require a comprehensive, whole-of-government strategy, with strong cross-agency collaboration, to advance U.S. biopharmaceutical competitiveness.

OMB’s proposed rule to increase the productivity and success of the U.S. scientific research establishment is commendable. But the rule in its totality would introduce dangerous and counterproductive revisions to the Uniform Guidance that would drastically reshape the American scientific enterprise for the worse and impose severe and long-lasting economic damage.

China has become an increasingly capable competitor in the global biopharmaceutical industry. To remain competitive, the United States should double down on policies to ensure that it offers the world’s leading environment to support private sector life sciences innovation.

Boeing and Airbus have long dominated the global commercial aircraft industry in production and innovation. But the rise of COMAC—China’s government-created, mercantilist-fueled national champion—threatens the foundations of market-based commercial aviation.

The EU has an array of discriminatory policies that target major U.S. tech firms, a legitimate basis for action under Section 301 of the Trade Act of 1974. U.S. policymakers should favor amicably negotiated solutions, but this tool is available as a last resort if necessary.

Country cases show that the Trump administration’s tariffs have had a paradoxical effect. They have given Washington short-term leverage in some bilateral negotiations, especially with countries seeking improved access to the U.S. market or deeper security and technology ties. But they have also accelerated a global search for optionality.

For policymakers to bolster their regional innovation capacity and global competitiveness, they first must know where they stand. This report benchmarks 48 regions across Albania, Bosnia and Herzegovina, North Macedonia, and Serbia on 13 commonly available innovation indicators.

U.S. automotive competitiveness has severely faltered. The federal government needs a comprehensive national strategy to revitalize the industry’s competitiveness, especially in the face of Chinese EVs.

In the postwar era, the national interest inherent in US trade policy pushed for globalization, first to compete with the Soviet Union, then to extend America’s “unipolar moment.” The rise of China changed this trajectory. But as the traditional FTA falls by the wayside, a new alternative template to redesign trade deals for the 21st century might be the "strategic techno-economic agreement."